Prime Medicine (PRME) News Today $2.89 +0.02 (+0.70%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Prime Medicine’s Promising Prospects and Potential Catalysts Justify Buy RatingJanuary 16 at 9:58 AM | markets.businessinsider.comStockNews.com Upgrades Prime Medicine (NYSE:PRME) to SellJanuary 15 at 2:18 AM | americanbankingnews.comStockNews.com Upgrades Prime Medicine (NYSE:PRME) to "Sell"StockNews.com upgraded Prime Medicine to a "sell" rating in a report on Wednesday.January 15 at 2:18 AM | marketbeat.comPrime Medicine (NYSE:PRME) Upgraded at StockNews.comStockNews.com raised shares of Prime Medicine to a "sell" rating in a report on Monday.January 6, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of "Buy" from AnalystsPrime Medicine, Inc. (NYSE:PRME - Get Free Report) has been assigned a consensus rating of "Buy" from the eleven ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, nine have given a buy recommendaJanuary 5, 2025 | marketbeat.comKuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law FirmJanuary 4, 2025 | markets.businessinsider.comIs Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In?December 31, 2024 | insidermonkey.comWhy Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now?December 30, 2024 | msn.comPrime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | msn.comPrime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | insidermonkey.comPrime Medicine (NYSE:PRME) Upgraded to "Sell" at StockNews.comStockNews.com upgraded Prime Medicine to a "sell" rating in a report on Tuesday.December 24, 2024 | marketbeat.comJMP Securities Initiates Coverage of Prime Medicine (PRME) with Market Outperform RecommendationDecember 11, 2024 | msn.comPrime Medicine (NYSE:PRME) Raised to Strong-Buy at Citizens JmpCitizens Jmp raised Prime Medicine to a "strong-buy" rating in a research report on Tuesday.December 11, 2024 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of "Moderate Buy" from BrokeragesPrime Medicine, Inc. (NYSE:PRME - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to thDecember 11, 2024 | marketbeat.comFmr LLC Has $14.49 Million Holdings in Prime Medicine, Inc. (NYSE:PRME)Fmr LLC cut its stake in shares of Prime Medicine, Inc. (NYSE:PRME - Free Report) by 4.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,743,312 shares of the company's stock after selling 184,541 shares during the peDecember 11, 2024 | marketbeat.comPrime Medicine, Inc.: Innovative Gene Editing Platform with Significant Market PotentialDecember 10, 2024 | markets.businessinsider.comJMP Securities Begins Coverage on Prime Medicine (NYSE:PRME)JMP Securities assumed coverage on Prime Medicine in a research report on Tuesday. They set an "outperform" rating and a $10.00 target price on the stock.December 10, 2024 | marketbeat.comVestal Point Capital LP Purchases 620,000 Shares of Prime Medicine, Inc. (NYSE:PRME)Vestal Point Capital LP increased its holdings in shares of Prime Medicine, Inc. (NYSE:PRME - Free Report) by 137.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,070,000 shares of the company's sNovember 29, 2024 | marketbeat.comPrime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing TherapiesNovember 26, 2024 | seekingalpha.comWilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep GenomicsNovember 21, 2024 | globenewswire.comFY2024 EPS Forecast for Prime Medicine Increased by AnalystPrime Medicine, Inc. (NYSE:PRME - Free Report) - Research analysts at Chardan Capital lifted their FY2024 earnings per share (EPS) estimates for Prime Medicine in a report released on Wednesday, November 13th. Chardan Capital analyst G. Livshits now forecasts that the company will earn ($1.73) peNovember 18, 2024 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Prime Medicine, Inc. (NYSE:PRME - Get Free Report) have earned an average rating of "Moderate Buy" from the nine analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and eight have assigned a buy recoNovember 16, 2024 | marketbeat.comPrime Medicine, Inc. (PRME) Gets a Hold from Morgan StanleyNovember 15, 2024 | markets.businessinsider.comFY2024 EPS Estimate for Prime Medicine Decreased by AnalystPrime Medicine, Inc. (NYSE:PRME - Free Report) - Equities research analysts at HC Wainwright reduced their FY2024 earnings estimates for Prime Medicine in a research note issued on Wednesday, November 13th. HC Wainwright analyst A. He now expects that the company will earn ($1.69) per share for tNovember 15, 2024 | marketbeat.comWedbush Forecasts Prime Medicine FY2024 EarningsPrime Medicine, Inc. (NYSE:PRME - Free Report) - Equities research analysts at Wedbush issued their FY2024 earnings per share estimates for Prime Medicine in a research note issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings of ($1.66)November 15, 2024 | marketbeat.comPrime Medicine Reports Q3 2024 Financial ProgressNovember 14, 2024 | markets.businessinsider.comIs Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?November 14, 2024 | finance.yahoo.comPrime Medicine, Inc.: Strategic Initiatives and Promising Developments Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comPrime Medicine, Inc. Receives Buy Rating from Arthur He CFA: Strategic Partnerships and Pipeline Focus Drive Promising Future ProspectsNovember 14, 2024 | markets.businessinsider.comPrime Medicine's (PRME) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Prime Medicine in a research report on Wednesday.November 13, 2024 | marketbeat.comPrime Medicine, Inc. (PRME) Receives a Buy from TD CowenNovember 13, 2024 | markets.businessinsider.comARK Investment Management LLC Reduces Holdings in Prime Medicine, Inc. (NYSE:PRME)ARK Investment Management LLC lowered its stake in shares of Prime Medicine, Inc. (NYSE:PRME - Free Report) by 7.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,660,719 shares of the company's stock after sellingNovember 8, 2024 | marketbeat.comPrime Medicine to Participate in Upcoming Investor ConferencesNovember 6, 2024 | globenewswire.com12 High-Growth Stocks That Could Deliver Parabolic ReturnsOctober 28, 2024 | fool.comPrime Medicine’s Gene Editing Breakthrough: High Efficiency and Therapeutic Potential in Liver-Specific DiseasesOctober 26, 2024 | markets.businessinsider.comPrime Medicine’s Promising Gene Editing Advancements Justify Buy RatingOctober 26, 2024 | markets.businessinsider.comPrime Medicine treatment of retinal dystrophy granted orphan designationOctober 26, 2024 | markets.businessinsider.comPrime Medicine Advances Gene Editing for Liver DiseasesOctober 25, 2024 | markets.businessinsider.comPrime Medicine presents data from multiple studies showcasing LNP platformOctober 25, 2024 | markets.businessinsider.comPrime Medicine (NYSE:PRME) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Prime Medicine in a report on Friday.October 25, 2024 | marketbeat.comPrime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual CongressOctober 24, 2024 | globenewswire.comPrime Medicine (NYSE:PRME) Shares Down 4.6% - Should You Sell?Prime Medicine (NYSE:PRME) Stock Price Down 4.6% - Should You Sell?October 22, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Up 15% - What's Next?Prime Medicine (NYSE:PRME) Trading Up 15% - Time to Buy?October 18, 2024 | marketbeat.comWhy I Keep Buying These 14 Incredible Growth StocksOctober 16, 2024 | fool.comPrime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific MeetingsOctober 15, 2024 | finance.yahoo.comPrime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific MeetingsOctober 15, 2024 | globenewswire.comPrime Medicine, Inc. (PRME) Receives a Hold from Morgan StanleyOctober 12, 2024 | markets.businessinsider.comMillennium Management LLC Has $6.84 Million Stock Holdings in Prime Medicine, Inc. (NYSE:PRME)Millennium Management LLC grew its holdings in Prime Medicine, Inc. (NYSE:PRME - Free Report) by 205.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,330,927 shares of the company's stock after purchasing an adOctober 11, 2024 | marketbeat.comPrime Medicine’s Strategic Alliances and Growth Potential Affirm Buy RatingOctober 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine on Strategic Partnerships and Technology Platform PotentialOctober 2, 2024 | markets.businessinsider.com Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address PRME Media Mentions By Week PRME Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRME News Sentiment▼0.400.72▲Average Medical News Sentiment PRME News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRME Articles This Week▼33▲PRME Articles Average Week Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Travere Therapeutics News Vir Biotechnology News Schrödinger News Xencor News Ardelyx News Nurix Therapeutics News Kiniksa Pharmaceuticals News Arcus Biosciences News Ocular Therapeutix News Maravai LifeSciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:PRME) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRME Stock Alerts